Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jonathan Epstein is active.

Publication


Featured researches published by Jonathan Epstein.


Journal of Clinical Epidemiology | 2015

Cross-cultural adaptation of the Health Education Impact Questionnaire: experimental study showed expert committee, not back-translation, added value

Jonathan Epstein; Richard H. Osborne; Gerald R. Elsworth; Dorcas E. Beaton; Francis Guillemin

OBJECTIVES To assess the contribution of back-translation and expert committee to the content and psychometric properties of a translated multidimensional questionnaire. STUDY DESIGN AND SETTING Recommendations for questionnaire translation include back-translation and expert committee, but their contribution to measurement properties is unknown. Four English to French translations of the Health Education Impact Questionnaire were generated with and without committee or back-translation. Face validity, acceptability, and structural properties were compared after random assignment to people with rheumatoid arthritis (N = 1,168), chronic renal failure (N = 2,368), and diabetes (N = 538). For face validity, 15 bilingual people compared translations quality with the original. Psychometric properties were examined using confirmatory factor analysis (metric and scalar invariance) and item response theory. RESULTS Qualitatively, there were five types of translation errors: style, intensity, frequency/time frame, breadth, and meaning. Bilingual assessors ranked best the translations with committee (P = 0.0026). All translations had good structural properties (root mean square error of approximation <0.05; comparative fit index [CFI], ≥0.899; and Tucker-Lewis index, ≥0.889). Full measurement invariance was observed between translations (ΔCFI ≤ 0.01) with metric invariance between translations and original (lowest ΔCFI = 0.022 between fully constrained models and models with free intercepts). Item characteristic curve analyses revealed no significant differences. CONCLUSION This is the first experimental evidence that back-translation has moderate impact, whereas expert committee helps to ensure accurate content.


Stroke | 2017

Cost-Effectiveness of Thrombectomy in Patients With Acute Ischemic Stroke: The THRACE Randomized Controlled Trial

Hamza Achit; Marc Soudant; Kossar Hosseini; Aurélie Bannay; Jonathan Epstein; Serge Bracard; Francis Guillemin

Background and Purpose— The benefit of mechanical thrombectomy added to intravenous thrombolysis (IVT) in patients with acute ischemic stroke has been largely demonstrated. However, evidence of the economic incentive of this strategy is still limited, especially in the context of a randomized controlled trial. We aimed to analyze whether mechanical thrombectomy combined with IVT (IVMT) is cost-effective when compared with IVT alone. Methods— Individual-level cost and outcome data were collected in the THRACE randomized controlled trial (Thrombectomie des Artères Cerébrales) including patients with acute ischemic stroke. Patients were assigned to receive IVT or IVMT. The primary outcomes were modified Rankin Scale score of functional independence at 90 days (score 0–2) and the EuroQol-5D quality-of-life score at 1 year. Results— Treating acute ischemic stroke with IVMT (n=200) versus IVT (n=202) increased the rate of functional independence by 10.9% (53.0% versus 42.1%; P=0.028), at an increased cost of


European Journal of Neurology | 2018

Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study

N. Chartier; Jonathan Epstein; M. Soudant; C. Dahan; M. Michaud; S. Pittion-Vouyovitch; Francis Guillemin; M. Debouverie; G. Mathey

2116 (&OV0556;1909), with no significant difference in mortality (12% versus 13%; P=0.70) or symptomatic intracranial hemorrhage (2% versus 2%; P=0.71). The cost per one averted case of disability was estimated at


Neuroepidemiology | 2017

Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study

Francis Guillemin; Cédric Baumann; Jonathan Epstein; Philippe Kerschen; Teresa Garot; Guillaume Mathey; Marc Debouverie

19 379 (&OV0556;17 480). The incremental cost per one quality-adjusted life year gained was


Joint Bone Spine | 2017

Hip Inflammation MRI Scoring System (HIMRISS) to predict response to hyaluronic acid injection in hip osteoarthritis

Nicolas Deseyne; Thierry Conrozier; Henri Lellouche; Bernard Maillet; Ulrich Weber; Jacob L. Jaremko; Joel Paschke; Jonathan Epstein; Walter P. Maksymowych; Damien Loeuille

14 881 (&OV0556;13 423). On sensitivity analysis, the probability of cost-effectiveness with IVMT was 84.1% in terms of cases of averted disability and 92.2% in terms of quality-adjusted life years. Conclusions— Based on randomized trial data, this study demonstrates that IVMT used to treat acute ischemic stroke is cost-effective when compared with IVT alone. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01062698.


Stroke | 2017

Cost-Effectiveness of Thrombectomy in Patients With Acute Ischemic Stroke

Hamza Achit; Marc Soudant; Kossar Hosseini; Aurélie Bannay; Jonathan Epstein; Serge Bracard; Francis Guillemin

Mitoxantrone (MITOX) has been used to treat patients with aggressive multiple sclerosis (MS) for decades. We aimed to describe the effectiveness and adverse events over 10 years post‐MITOX in patients with relapsing and progressive MS from an exhaustive real‐life database.


Revue du Rhumatisme | 2018

Prédiction de la réponse à l’injection d’acide hyaluronique dans la coxarthrose par le score IRM HIMRISS

Nicolas Deseyne; Thierry Conrozier; Henri Lellouche; Bernard Maillet; Ulrich Weber; Jacob L. Jaremko; Joel Paschke; Jonathan Epstein; Walter P. Maksymowych; Damien Loeuille

Background: Late-onset multiple sclerosis (LOMS) frequently features a primary progressive (PP) course, strongly predicting severe disability. In this population-based cohort, we estimated the prognostic role of age at multiple sclerosis (MS) onset, independent of PP course, on disability progression. Methods: The association of age at disease onset (adult, <50 years [AOMS], vs. late, ≥50 years [LOMS]) and time to Expanded Disability Status Scale (EDSS) score 4 and 6 was estimated by Cox regression modelling. Results: Among 3,597 patients, 245 had LOMS. Relapsing-remitting (RR) disease was less frequent with LOMS than AOMS (51.8 vs. 90.8%, p < 0.0001). PP course, LOMS and male gender predicted short time to EDSS 4 and 6. Worse outcome with LOMS (time to EDSS 4 and 6, HR 2.0 [95% CI 1.7-2.4] and 2.3 [1.9-2.9]) was independent of PP course or male gender. LOMS had greater impact on RR than PP disease (time to EDSS 4 and 6, HR 3.1 [2.3-4.0] and 4.0 [2.9-5.6]). Only LOMS predicted time from EDSS 4 to 6 (p < 0.0001). Conclusions: Late onset MS was strongly associated with poor prognosis, independent of initial disease course, in predicting the disability progression along time.


Revue Neurologique | 2018

Caractéristiques et prise en charge thérapeutique des patients atteints de sclérose en plaques rémittente-récurrente – Données issues du Registre Lorrain des Scléroses en Plaques

Jonathan Epstein; Guillaume Mathey; Francis Guillemin; Marc Debouverie; Bertrand Tehard; Laurence Bitoun; Paul Henri Depoortere

OBJECTIVE To assess predictors of response, according to hip MRI inflammatory scoring system (HIMRISS), in a sample of patients with hip osteoarthritis (OA) treated by hyaluronic acid (HA) injection. METHOD Sixty patients with hip OA were included. Clinical outcomes were assessed at baseline and three months after HA injection by WOMAC. On hip MRI performed before HA injection, bone marrow lesion (BML) and synovitis were assessed by HIMRISS by four readers. The inter-reader reliability of HIMRISS was for HIMRISS total, acetabular BML, femoral BML and synovitis-effusion respectively 0.86, 0.64, 0.83 and 0.78. Associations between MRI features and clinical data were assessed. Logistic regression (univariate and multivariate) was used to explore associations between MRI features and response to HA injection, according to WOMAC50 response at three months. RESULTS In total, 45.5% of patients met WOMAC50 response. Five adverse events were reported. At baseline, WOMAC function correlated significantly to HIMRISS synovitis-effusion (r=0.27, P=0.03). In univariate analysis, BML femoral according to binary assessment (P=0.025), HIMRISS BML femoral (P=0.0038), HIMRISS BML acetabular (P=0.042), HIMRISS total (P=0.0092) were associated negatively with WOMAC50 response. In multivariate analysis, adjusted for age and BMI, HIMRISS femoral BML (P=0.02) and HIMRISS total (P=0.016) were negatively associated with response. At a HIMRISS threshold of<15, 82% of patients were responders, with specificity SP=0.97, sensitivity SN=0.39, and positive and negative predictive values of 0.91 and 0.64, respectively. CONCLUSION HIMRISS is reliable for total scores and sub-domains. It permits identification of responders to HA injection in hip OA patients.


Revue Neurologique | 2018

Caractéristiques et prise en charge thérapeutique des patients atteints de sclérose en plaques primaire progressive – Données issues du Registre Lorrain des Scléroses en Plaques (RelSEP)

Jonathan Epstein; Guillaume Mathey; Francis Guillemin; Marc Debouverie; Laurence Bitoun; Paul Henri Depoortere; David Pau


Revue D Epidemiologie Et De Sante Publique | 2017

Méthode Bayésienne pour l’analyse des propriétés diagnostiques des immunoglobulines G dans le cadre d’une sclérose en plaques

S. Gamraoui; G. Mathey; M. Debouverie; C. Armand; R. Anxionnat; Francis Guillemin; Jonathan Epstein

Collaboration


Dive into the Jonathan Epstein's collaboration.

Top Co-Authors

Avatar

Francis Guillemin

Hospital for Special Surgery

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kossar Hosseini

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge